ORIGINAL,O
RESEARCH,O
LETTER,O
of,O
first,ORDINAL
case,O
in,O
Foshan,CITY
.,O
China,COUNTRY
The,O
out,O
‐,O
break,O
of,O
the,O
2019,DATE
new,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
has,O
caught,O
worldwide,O
attention,O
.,O
Since,O
December,DATE
2019,DATE
.,O
several,O
pneumonia,CAUSE_OF_DEATH
cases,O
of,O
un,O
‐,O
known,O
origin,O
have,O
been,O
found,O
in,O
hospitals,O
in,O
Wuhan,CITY
.,O
Hubei,STATE_OR_PROVINCE
conduct,O
pathogen,O
tests,O
on,O
alveolar,O
lavage,O
fluid,O
.,O
throat,O
swabs,O
.,O
blood,O
and,O
other,O
samples,O
by,O
methods,O
of,O
virus,O
isolation,O
.,O
nucleic,O
acid,O
testing,O
and,O
genome,O
sequencing,O
.,O
among,O
others,O
.,O
On,O
7,DATE
January,DATE
2020,DATE
.,O
a,O
novel,O
coronavirus,O
.,O
previously,DATE
undetected,O
in,O
humans,O
.,O
was,O
isolated,O
and,O
its,O
full,O
genome,O
sequence,O
was,O
decoded,O
[,O
1,NUMBER
],O
.,O
On,O
12,DATE
January,DATE
2020,DATE
.,O
the,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
(,O
WHO,O
),O
officially,O
named,O
this,O
new,O
coronavirus,O
causing,O
the,O
outbreak,O
of,O
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
the,O
2019,DATE
new,O
coronavirus,O
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
Since,O
the,DATE
end,DATE
of,DATE
December,DATE
2019,DATE
.,O
the,O
number,O
of,O
cases,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
has,O
increased,O
rapidly,O
.,O
As,O
of,O
24:00,TIME
h,O
on,O
13,DATE
February,DATE
.,O
there,O
were,O
63,NUMBER
946,NUMBER
con,O
‐,O
firmed,O
cases,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
acute,O
respiratory,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
in,O
China,COUNTRY
and,O
162,NUMBER
confirmed,O
cases,O
in,O
26,NUMBER
other,O
countries,O
.,O
WHO,O
has,O
classified,O
this,O
outbreak,O
as,O
a,O
public,O
health,O
emergency,O
of,O
international,O
con,O
‐,O
cern,O
.,O
The,O
outbreak,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
seriously,O
endangers,O
human,O
health,O
and,O
life,O
.,O
affects,O
the,O
social,O
order,O
.,O
and,O
causes,O
substantial,O
eco,O
‐,O
nomic,O
losses,O
.,O
Currently,DATE
.,O
there,O
are,O
no,O
effective,O
drugs,CRIMINAL_CHARGE
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
and,O
its,O
primary,O
treatment,O
is,O
only,O
symptomatic,O
and,O
support,O
‐,O
ive,O
.,O
Critically,O
ill,O
patients,O
are,O
in,O
danger,O
at,O
any,O
time,O
.,O
Timely,O
measures,O
to,O
prevent,O
the,O
occurrence,O
of,O
severe,O
pneumonia,CAUSE_OF_DEATH
and,O
the,O
development,O
of,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
are,O
the,O
key,O
to,O
the,O
treatment,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Although,O
the,O
pathogenesis,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
unclear,O
.,O
its,O
molecular,O
mechanism,O
of,O
infecting,O
human,O
respiratory,O
epithelial,O
cells,O
through,O
the,O
Spike,O
protein,O
is,O
the,O
same,O
as,O
that,O
of,O
SARS,O
‐,O
CoV,O
‐,O
1,NUMBER
and,O
the,O
symptoms,O
caused,O
by,O
its,O
infec,O
‐,O
tion,O
are,O
similar,O
to,O
those,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
.,O
At,O
the,DATE
end,DATE
of,DATE
2002,DATE
.,O
our,O
hospital,O
had,O
hospitalised,O
and,O
cured,O
the,O
worlds,O
first,ORDINAL
SARS,MISC
patient,O
.,O
and,O
the,O
total,O
number,O
of,O
these,O
cases,O
admitted,O
and,O
confirmed,O
would,O
surpass,O
110,NUMBER
.,O
No,O
hospi,O
‐,O
talised,O
patients,O
died,O
and,O
all,O
were,O
eventually,O
discharged,O
.,O
Our,O
hospital,O
has,O
gained,O
meaningful,O
experience,O
in,O
the,O
treatment,O
of,O
se,O
‐,O
vere,O
pneumonia,CAUSE_OF_DEATH
caused,O
by,O
coronavirus,O
infection,CAUSE_OF_DEATH
.,O
To,O
provide,O
a,O
ref,O
‐,O
erence,O
for,O
the,O
treatment,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
we,O
report,O
the,O
detailed,O
history,O
.,O
onset,O
.,O
disease,CAUSE_OF_DEATH
evolution,O
.,O
diagnosis,O
and,O
treatment,O
of,O
the,O
first,ORDINAL
case,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
Foshan,CITY
.,O
China,COUNTRY
.,O
This,O
patient,O
was,O
a,O
40,NUMBER
‐,O
year,DURATION
‐,O
old,O
man,O
with,O
no,O
underlying,O
disease,CAUSE_OF_DEATH
other,O
than,O
hyperten,O
‐,O
sion,O
.,O
The,O
patient,O
had,O
no,O
recent,O
travel,O
history,O
to,O
Hubei,STATE_OR_PROVINCE
Province,LOCATION
or,O
Wuhan,CITY
but,O
his,O
wife,O
had,O
recently,DATE
travelled,O
to,O
Wuhan,CITY
and,O
re,O
‐,O
turned,O
to,O
Foshan,CITY
City,LOCATION
(,O
Guangdong,STATE_OR_PROVINCE
Province,LOCATION
),O
on,O
6,DATE
January,DATE
2020,DATE
.,O
During,O
her,O
trip,O
.,O
she,O
had,O
a,O
low,O
fever,CAUSE_OF_DEATH
and,O
cough,O
but,O
symptoms,O
were,O
relieved,O
within,O
1,DURATION
week,DURATION
without,O
any,O
treatments,O
.,O
The,O
patient,O
went,O
to,O
Guangzhou,CITY
South,LOCATION
railway,O
station,O
.,O
a,O
crowded,O
high,O
‐,O
speed,O
rail,O
hub,O
.,O
to,O
pick,O
up,O
his,O
wife,O
.,O
On,O
10,DATE
January,DATE
2020,DATE
.,O
the,O
patient,O
began,O
to,O
get,O
sick,O
.,O
with,O
fever,CAUSE_OF_DEATH
as,O
the,O
initial,O
symptom,O
.,O
There,O
was,O
no,O
dis,O
‐,O
cernible,O
pattern,O
of,O
fever,CAUSE_OF_DEATH
.,O
and,O
the,O
highest,O
temperature,O
was,O
39.0,NUMBER
C,O
.,O
accompanied,O
by,O
chills,O
and,O
intermittent,O
dry,O
cough,O
.,O
However,O
.,O
the,O
patient,O
did,O
not,O
take,O
the,O
disease,CAUSE_OF_DEATH
seriously,O
until,O
1,DATE
week,DATE
later,DATE
.,O
when,O
his,O
symptoms,O
gradually,O
worsened,O
with,O
shortness,O
of,O
breath,O
.,O
and,O
then,O
he,O
went,O
to,O
the,O
local,O
community,O
hospital,O
for,O
treatment,O
.,O
Test,O
results,O
showed,O
high,O
procalcitonin,O
and,O
hypoxia,O
.,O
The,O
local,O
physicians,O
treated,O
him,O
for,O
bacterial,O
pneumonia,CAUSE_OF_DEATH
but,O
the,O
symptoms,O
did,O
not,O
improve,O
.,O
as,O
he,O
still,O
had,O
a,O
fever,CAUSE_OF_DEATH
.,O
worsened,O
shortness,O
of,O
breath,O
and,O
diarrhoea,CAUSE_OF_DEATH
.,O
The,O
first,ORDINAL
case,O
of,O
#COVID19,O
in,O
Foshan,CITY
pro,O
‐,O
vides,O
a,O
reference,O
for,O
the,O
treatment,O
of,O
severe,O
ERJ,MISC
Open,MISC
Res,O
2020,DATE
;,O
6,NUMBER
:,O
00090,NUMBER
‐,O
2020,DATE
ORIGINAL,O
RESEARCH,O
LETTER,O
|,O
L.,O
ZHOU,O
ET,O
AL,O
.,O
Consid,O
‐,O
ering,O
that,O
he,O
recently,DATE
had,O
been,O
in,O
close,O
contact,O
with,O
people,O
from,O
the,O
epidemic,O
area,O
.,O
the,O
local,O
physicians,O
thought,O
he,O
might,O
have,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Because,O
his,O
shortness,O
of,O
breath,O
gradually,O
worsened,O
and,O
given,O
the,O
risk,O
of,O
progression,O
to,O
ARDS,O
.,O
he,O
was,O
transferred,O
to,O
our,O
hospital,O
for,O
further,O
treatment,O
.,O
When,O
the,O
patient,O
was,O
admit,O
‐,O
ted,O
to,O
our,O
hospital,O
on,O
20,DATE
January,DATE
2020,DATE
.,O
he,O
was,O
quarantined,O
as,O
a,O
suspected,O
patient,O
.,O
and,O
strict,O
protective,O
measures,O
were,O
taken,O
for,O
his,O
attending,O
doctors,O
and,O
nurses,O
.,O
On,O
that,O
day,DURATION
.,O
he,O
had,O
a,O
chest,O
computed,O
tomography,O
(,O
CT,STATE_OR_PROVINCE
),O
scan,O
and,O
the,O
result,O
indicated,O
multiple,O
inflammatory,O
exudation,O
in,O
patient,O
was,O
sent,O
to,O
Foshan,CITY
Centre,LOCATION
for,O
Disease,CAUSE_OF_DEATH
Control,O
for,O
the,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
assay,O
.,O
12,NUMBER
h,O
later,O
.,O
the,O
result,O
Octapharma,O
500,NUMBER
mL,O
once,DATE
daily,SET
ivgtt,O
.,O
Thymosin,O
1.6,NUMBER
mg,O
once,DATE
daily,SET
ih,O
.,O
Moxioxacin,O
400,NUMBER
mg,O
once,DATE
daily,SET
ivgtt,O
.,O
Piperacillin,O
sodi,O
‐,O
um,O
/,O
tazobactam,O
sodium,O
4,NUMBER
g,O
/,O
0.5,NUMBER
g,O
every,O
8,NUMBER
h,O
ivgtt,O
.,O
Lopinavir,LOCATION
/,O
Liton,ORGANIZATION
‐,O
avir,O
200,NUMBER
mg,O
/,O
50,NUMBER
mg,O
twice,O
daily,SET
by,O
mouth,O
Oseltamivir,PERSON
75,NUMBER
mg,O
twice,O
daily,SET
by,O
mouth,O
Hapgen,PERSON
30,NUMBER
g,O
twice,O
daily,SET
inh,O
.,O
HHFNC,ORGANIZATION
50,NUMBER
Lmin1,O
45,PERCENT
%,PERCENT
31C,O
NC,STATE_OR_PROVINCE
2,NUMBER
Lmin1,O
NC,STATE_OR_PROVINCE
4,NUMBER
Lmin1,O
NC,STATE_OR_PROVINCE
4,NUMBER
Lmin1,O
NC,STATE_OR_PROVINCE
2,NUMBER
Lmin1,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
posi,O
‐,O
tive,O
in,O
throat,O
swab,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
positive,O
in,O
respiratory,O
secretions,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
negative,O
in,O
throat,O
swab,O
Time,O
days,DURATION
Oxygen,O
partial,O
pres,O
‐,O
sure,O
mmHg,O
Time,O
days,DURATION
Time,O
days,DURATION
Time,O
days,DURATION
Time,O
days,DURATION
Time,O
days,DURATION
Heart,O
rate,O
beats,O
per,O
min,DURATION
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
pgmL1,O
Time,O
days,DURATION
Time,O
days,DURATION
Body,O
tempera,O
‐,O
ture,O
C,O
Respiratory,O
rate,O
breaths,O
per,O
min,DURATION
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
negative,O
in,O
faeces,O
and,O
urine,O
Oxygenation,MISC
index,O
mmHg,PERCENT
%,PERCENT
1,NUMBER
White,O
blood,O
count,TITLE
109L1,O
PCT,O
ngmL1,O
Lactic,MISC
acid,O
mmolL1,O
Time,O
days,DURATION
Time,O
days,DURATION
along,O
.,O
c,O
),O
Pa,STATE_OR_PROVINCE
‐,O
tient,O
status,O
tracking,O
during,O
treatment,O
.,O
including,O
lactic,O
acid,O
level,O
.,O
procalcitonin,O
(,O
PCT,O
),O
level,O
.,O
lymphocyte,O
percentage,O
value,O
.,O
white,O
blood,O
cell,O
count,TITLE
.,O
interleukin,O
(,O
IL,STATE_OR_PROVINCE
),O
‐,O
6,NUMBER
level,O
.,O
oxygenation,O
in,O
‐,O
dex,O
level,O
.,O
oxygen,O
partial,O
pressure,O
.,O
heart,O
rate,O
.,O
respiratory,O
rate,O
and,O
body,O
temperature,O
.,O
Green,O
lines,O
represent,O
the,O
limits,O
of,O
normal,O
values,O
and,O
light,O
shading,O
represents,O
the,O
normal,O
range,O
.,O
HHNFC,O
:,O
hu,O
‐,O
midified,O
high,O
‐,O
flow,O
nasal,O
cannula,O
;,O
NC,STATE_OR_PROVINCE
:,O
nasal,O
cannula,O
;,O
ivgtt,O
:,O
in,O
‐,O
travenous,O
glucose,O
drip,O
;,O
ih,O
:,O
hypodermic,O
injection,O
;,O
inh,O
inhalation,O
.,O
ORIGINAL,O
RESEARCH,O
LETTER,O
|,O
L.,O
ZHOU,O
ET,O
AL,O
.,O
was,O
positive,O
for,O
the,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
sequence,O
detected,O
by,O
RT,O
‐,O
PCR,O
assay,O
.,O
The,O
patient,O
was,O
di,O
‐,O
agnosed,O
as,O
suffering,O
from,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
The,O
patient,O
had,O
a,O
rapid,O
respiratory,O
rate,O
(,O
>,O
30,NUMBER
breaths,O
per,O
min,DURATION
),O
.,O
respiratory,O
hospital,O
days,DURATION
15,NUMBER
.,O
we,O
treated,O
the,O
patient,O
with,O
normal,O
nasal,O
cannula,O
oxygen,O
ther,O
‐,O
apy,O
(,O
4,NUMBER
Lmin1,O
),O
.,O
On,O
days,DURATION
5,NUMBER
and,O
6,NUMBER
.,O
nasal,O
cannula,O
oxygen,O
therapy,O
was,O
changed,O
to,O
2,NUMBER
Lmin1,O
.,O
However,O
.,O
on,O
day,DURATION
7,NUMBER
.,O
the,O
patients,O
oxygenation,O
index,O
decreased,O
to,O
278,NUMBER
mmHg,PERCENT
%,PERCENT
1,NUMBER
.,O
SOFA,O
(,O
Sepsis,CAUSE_OF_DEATH
‐,O
Related,O
Organ,O
Failure,O
Assessment,O
),O
score,O
2,NUMBER
and,O
CURB,O
‐,O
65,NUMBER
score,NUMBER
0,NUMBER
.,O
The,O
patient,O
developed,O
acute,O
respiratory,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
but,O
did,O
not,O
progress,O
to,O
ARDS,O
.,O
We,O
began,O
to,O
treat,O
him,O
with,O
humidified,O
high,O
‐,O
flow,O
nasal,O
cannula,O
(,O
HHFNC,O
),O
oxy,O
‐,O
gen,O
therapy,O
(,O
31C,O
.,O
50,NUMBER
Lmin1,O
.,O
45,PERCENT
%,PERCENT
oxygen,O
concentration,O
),O
for,O
48,NUMBER
h.,O
The,O
patients,O
symptoms,O
were,O
beginning,O
to,O
relieve,O
by,O
day,DURATION
9,NUMBER
.,O
and,O
we,O
continued,O
ordinary,O
nasal,O
cannula,O
oxygen,O
therapy,O
at,O
4,NUMBER
Lmin1,O
on,O
days,DURATION
914,NUMBER
and,O
2,NUMBER
Lmin1,O
on,O
days,DATE
1417,DATE
.,O
The,O
antivirus,O
therapy,O
was,O
as,O
follow,O
:,O
oseltamivir,O
was,O
administered,O
orally,O
at,O
75,NUMBER
mg,O
twice,O
daily,SET
from,O
day,DURATION
1,NUMBER
to,O
day,DURATION
6,NUMBER
;,O
lopinavir,O
/,O
litonavir,O
orally,O
at,O
200,NUMBER
mg,O
/,O
50,NUMBER
mg,O
twice,O
daily,SET
from,O
day,DURATION
7,NUMBER
to,O
day,DURATION
13,NUMBER
;,O
and,O
hapgen,O
atomised,O
30,NUMBER
g,O
every,O
12,NUMBER
h,O
from,O
day,DURATION
1,NUMBER
to,O
day,DURATION
14,NUMBER
.,O
To,O
enhance,O
immunity,O
.,O
the,O
patient,O
was,O
hypodermically,O
injected,O
with,O
thymosin,O
1.6,NUMBER
mg,O
once,DATE
daily,SET
from,O
day,DURATION
3,NUMBER
to,O
day,DURATION
14,NUMBER
.,O
To,O
prevent,O
bacterial,O
infection,CAUSE_OF_DEATH
.,O
the,O
patient,O
was,O
giv,O
‐,O
en,O
moxifloxacin,O
intravenous,O
drip,O
400,NUMBER
mg,O
once,DATE
daily,SET
from,O
day,DURATION
1,NUMBER
to,O
10,NUMBER
and,O
piperacillin,O
sodium,O
/,O
tazobactam,O
sodium,O
(,O
8/1,NUMBER
),O
4.5,NUMBER
g,O
every,O
8,NUMBER
h,O
ivgtt,O
from,O
day,DATE
11,DATE
to,DATE
day,DATE
18,DATE
.,O
From,O
day,DURATION
7,NUMBER
to,O
day,DURATION
10,NUMBER
.,O
the,O
patient,O
was,O
given,O
20,PERCENT
%,PERCENT
human,O
serum,O
albumin,O
(,O
Octapharma,O
),O
intravenous,O
drip,O
50,NUMBER
mL,O
once,DATE
daily,SET
.,O
Full,O
drugs,CRIMINAL_CHARGE
.,O
function,O
.,O
inflammation,O
indicators,O
.,O
blood,O
routine,O
indicators,O
and,O
other,O
parameters,O
were,O
checked,O
regu,O
‐,O
larly,O
negative,O
and,O
the,O
two,NUMBER
subsequent,O
tests,O
on,O
day,DURATION
17,NUMBER
were,O
also,O
negative,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
from,O
patients,O
faeces,O
and,O
urine,O
.,O
At,O
the,O
same,O
time,O
.,O
his,O
fever,CAUSE_OF_DEATH
and,O
shortness,O
of,O
breath,O
were,O
significantly,O
relieved,O
.,O
and,O
his,O
oxygenation,O
improved,O
.,O
Oxygen,O
therapy,O
was,O
no,O
longer,O
required,O
.,O
and,O
the,O
patient,O
was,O
declared,O
clinically,O
cured,O
and,O
discharged,O
from,O
hospital,O
in,O
day,DATE
18,DATE
(,O
6,DATE
February,DATE
2020,DATE
),O
.,O
Gluco,O
‐,O
corticoids,O
were,O
not,O
used,O
throughout,O
the,O
treatment,O
.,O
The,O
infection,CAUSE_OF_DEATH
source,O
of,O
the,O
patient,O
deserves,O
our,O
attention,O
.,O
Before,O
the,O
illness,CAUSE_OF_DEATH
onset,O
.,O
the,O
patient,O
had,O
no,O
travel,O
history,O
to,O
the,O
epidemic,O
area,O
(,O
Wuhan,CITY
),O
with,O
community,O
transmission,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
and,O
had,O
no,O
con,O
‐,O
tact,O
with,O
confirmed,O
cases,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
His,O
illness,CAUSE_OF_DEATH
began,O
after,O
he,O
went,O
to,O
a,O
high,O
‐,O
speed,O
train,CRIMINAL_CHARGE
station,O
to,O
pick,O
up,O
his,O
wife,O
.,O
who,O
had,O
returned,O
from,O
the,O
epidemic,O
area,O
of,O
Wuhan,CITY
.,O
His,O
wife,O
developed,O
a,O
low,O
fever,CAUSE_OF_DEATH
cough,O
on,O
4,DATE
January,DATE
and,O
her,O
body,O
temperature,O
decreased,O
to,O
normal,O
values,O
after,O
returning,O
to,O
Foshan,CITY
.,O
She,O
was,O
al,O
‐,O
so,O
admitted,O
to,O
the,O
hospital,O
for,O
isolation,O
on,O
2,DATE
January,DATE
;,O
the,O
re,O
‐,O
sult,O
of,O
chest,O
examination,O
was,O
normal,O
and,O
the,O
results,O
of,O
two,NUMBER
throat,O
swabs,O
(,O
which,O
were,O
obtained,O
at,O
an,O
interval,O
of,O
24,NUMBER
h,O
),O
tested,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
nucleic,O
acid,O
by,O
RT,O
‐,O
PCR,O
assays,O
were,O
both,O
negative,O
.,O
Although,O
the,O
patients,O
wife,O
can,O
not,O
be,O
ruled,O
out,O
as,O
the,O
direct,O
source,O
of,O
infection,CAUSE_OF_DEATH
.,O
the,O
infection,CAUSE_OF_DEATH
source,O
may,O
have,O
also,O
come,O
from,O
other,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
carriers,O
from,O
the,O
epidemic,O
area,O
of,O
Wuhan,CITY
in,O
the,O
crowded,O
high,O
‐,O
speed,O
railway,O
station,O
.,O
In,O
conclusion,O
.,O
this,O
patient,O
is,O
a,O
typical,O
case,O
of,O
human,O
‐,O
to,O
‐,O
human,O
transmission,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Other,O
relatives,O
who,O
had,O
close,O
contact,O
with,O
the,O
patient,O
were,O
not,O
infected,O
during,O
the,O
isolation,O
period,O
.,O
The,O
patient,O
is,O
the,O
earliest,O
confirmed,O
case,O
of,O
human,O
‐,O
to,O
‐,O
human,O
transmission,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
‐,O
fection,O
outside,O
the,O
epidemic,O
area,O
in,O
China,COUNTRY
.,O
When,O
the,O
patient,O
was,O
diagnosed,O
.,O
the,O
provinces,O
and,O
cities,O
in,O
China,COUNTRY
also,O
rapidly,O
started,O
implementing,O
major,O
public,O
health,O
measures,O
to,O
prevent,O
further,O
spread,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
The,O
patient,O
had,O
multiple,O
organ,O
damage,O
and,O
the,O
main,O
target,O
organ,O
was,O
the,O
lung,O
.,O
After,O
14,DURATION
days,DURATION
of,O
the,O
course,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
there,O
were,O
still,O
changes,O
in,O
the,O
pulmonary,O
imaging,O
progress,O
when,O
the,O
respiratory,O
nucleic,O
acid,O
had,O
begun,O
to,O
turn,O
neg,O
‐,O
ative,O
.,O
and,O
the,O
other,O
organs,O
had,O
also,O
recovered,O
from,O
the,O
damage,O
.,O
The,O
pulmonary,O
imaging,O
progress,O
might,O
be,O
related,O
to,O
the,O
incomplete,O
clearance,O
of,O
the,O
virus,O
.,O
The,O
nucleic,O
acid,O
of,O
respiratory,O
secre,O
‐,O
tions,O
.,O
in,O
this,O
case,O
.,O
turned,O
negative,O
around,O
the,DATE
16th,DATE
day,DATE
of,O
the,O
course,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
which,O
was,O
accompanied,O
by,O
the,O
improvement,O
of,O
pulmonary,O
imaging,O
.,O
The,O
clinical,O
symptoms,O
of,O
the,O
disease,CAUSE_OF_DEATH
were,O
not,O
consistent,O
with,O
the,O
imaging,O
changes,O
but,O
more,O
consistent,O
with,O
the,O
respiratory,O
nucleic,O
acid,O
conversion,O
to,O
negative,O
.,O
According,O
to,O
the,O
disease,CAUSE_OF_DEATH
development,O
of,O
this,O
patient,O
.,O
the,O
natural,O
course,O
of,O
the,O
severe,O
case,O
was,O
as,O
long,O
as,O
18,DURATION
days,DURATION
and,O
the,O
disease,CAUSE_OF_DEATH
did,O
not,O
enter,O
the,O
progressive,IDEOLOGY
stage,O
until,O
1,DURATION
week,DURATION
after,O
the,O
onset,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
respiratory,O
secretions,O
still,O
tested,O
positive,O
for,O
the,O
nucleic,O
acid,O
RT,O
‐,O
PCR,O
test,O
2,DURATION
days,DURATION
after,O
the,O
use,O
of,O
lopinavir,O
the,O
natural,O
progression,O
taking,O
into,O
account,O
the,O
point,O
at,O
which,O
the,O
respiratory,O
nucleic,O
acid,O
tests,O
began,O
to,O
turn,O
negative,O
.,O
Therefore,O
.,O
there,O
is,O
no,O
evidence,O
that,O
patients,O
respond,O
well,O
to,O
treatment,O
.,O
and,O
there,O
is,O
no,O
On,O
day,DURATION
7,NUMBER
after,O
the,O
onset,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
the,O
patient,O
started,O
to,O
have,O
acute,O
respiratory,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
.,O
which,O
lasted,O
for,O
1,NUMBER
week,DURATION
.,O
However,O
.,O
after,O
HHFNC,O
oxygen,O
therapy,O
.,O
intermittent,O
noninva,O
‐,O
sive,O
ventilation,O
and,O
other,O
supportive,O
treatment,O
.,O
the,O
condition,O
of,O
the,O
patient,O
gradually,O
stabilised,O
.,O
and,O
thus,O
invasive,O
mechanical,O
ventilation,O
therapy,O
was,O
avoided,O
.,O
Studies,O
have,O
shown,O
that,O
HHFNC,PERSON
oxygen,O
therapy,O
can,O
reduce,O
the,O
ORIGINAL,O
RESEARCH,O
LETTER,O
|,O
L.,PERSON
ZHOU,PERSON
ET,O
AL,O
.,O
intubation,O
rate,O
of,O
patients,O
with,O
acute,O
respiratory,O
fail,O
‐,O
ure,O
.,O
which,O
can,O
not,O
only,O
improve,O
the,O
symptoms,O
of,O
hypoxia,O
and,O
avoid,O
carbon,O
dioxide,O
retention,O
but,O
also,O
provide,O
some,O
positive,O
end,O
‐,O
expi,O
‐,O
ratory,O
pressure,O
to,O
avoid,O
atelectasis,O
[,O
2,NUMBER
],O
.,O
When,O
the,O
patients,O
have,O
obvious,O
shortness,O
of,O
breath,O
that,O
can,O
not,O
be,O
alleviated,O
by,O
ordinary,O
oxygen,O
therapy,O
.,O
active,O
and,O
full,O
respiratory,O
support,O
should,O
be,O
ap,O
‐,O
plied,O
.,O
HHFNC,O
oxygen,O
may,O
be,O
the,O
most,O
valuable,O
for,O
lung,O
protection,O
and,O
recovery,O
.,O
Meanwhile,O
.,O
active,O
atomisation,O
treatment,O
may,O
also,O
be,O
beneficial,O
in,O
improving,O
the,O
condition,O
.,O
which,O
has,O
been,O
reported,O
in,O
Germany,COUNTRY
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
[,O
3,NUMBER
],O
.,O
In,O
this,O
case,O
of,O
pneumonia,CAUSE_OF_DEATH
.,O
the,O
char,O
‐,O
acteristics,O
of,O
lung,O
lesions,O
were,O
different,O
from,O
ARDS,O
caused,O
by,O
traditional,O
community,O
‐,O
acquired,O
pneumonia,CAUSE_OF_DEATH
and,O
the,O
tissue,O
functions,O
of,O
noninvolved,O
lung,O
were,O
basically,O
normal,O
.,O
so,O
there,O
were,O
mild,O
symptoms,O
and,O
serious,O
lung,O
imaging,O
changes,O
[,O
4,NUMBER
],O
.,O
Notably,O
.,O
regard,O
‐,O
ing,O
the,O
blood,O
analysis,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
mainly,O
characterised,O
by,O
low,O
numbers,O
of,O
both,O
white,O
blood,O
cells,O
and,O
lymphocytes,O
.,O
Thymosin,O
a1,O
‐,O
a,O
.,O
as,O
a,O
widely,O
used,O
immunomodulatory,O
agent,O
.,O
was,O
given,O
to,O
the,O
patient,O
to,O
enhance,O
his,O
immunity,O
during,O
the,O
treatment,O
[,O
5,NUMBER
],O
.,O
After,O
injec,O
‐,O
tion,O
.,O
the,O
number,O
of,O
lymphocytes,O
and,O
the,O
lymphocyte,O
percentage,O
of,O
the,O
patient,O
returned,O
to,O
normal,O
.,O
and,O
no,O
drug,O
‐,O
related,O
fever,CAUSE_OF_DEATH
or,O
al,O
‐,O
lergic,O
reactions,O
were,O
detected,O
.,O
After,O
this,O
treatment,O
.,O
the,O
serum,O
interleukin,O
(,O
IL,STATE_OR_PROVINCE
),O
‐,O
6,NUMBER
of,O
the,O
patient,O
decreased,O
gradually,O
and,O
his,O
clinical,O
symptoms,O
were,O
relieved,O
.,O
which,O
was,O
consistent,O
with,O
the,O
nature,O
of,O
ARDS,O
.,O
an,O
acute,O
inflammatory,O
clinical,O
syndrome,O
per,O
se,O
[,O
6,NUMBER
],O
.,O
The,O
patients,O
leukocyte,O
count,TITLE
was,O
low,O
and,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
was,O
high,O
at,O
the,O
early,O
stage,O
.,O
but,O
his,O
overall,O
serum,O
inflammatory,O
level,O
was,O
less,O
severe,O
than,O
those,O
of,O
patients,O
with,O
bacterial,O
sepsis,CAUSE_OF_DEATH
or,O
ARDS,O
.,O
The,O
pathogenesis,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
unknown,O
but,O
its,O
molecular,O
mech,O
‐,O
anism,O
for,O
infecting,O
human,O
respiratory,O
epithelial,O
cells,O
through,O
Spike,O
protein,O
is,O
the,O
same,O
as,O
that,O
of,O
SARS,O
‐,O
CoV,O
‐,O
1,NUMBER
and,O
the,O
infection,CAUSE_OF_DEATH
symptoms,O
are,O
similar,O
to,O
those,O
of,O
SARS,O
.,O
The,O
overall,O
mortality,O
of,O
SARS,O
was,O
11,PERCENT
%,PERCENT
.,O
whereas,O
the,O
mortality,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
2,PERCENT
%,PERCENT
.,O
However,O
.,O
the,O
total,O
number,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
cases,O
has,O
exceeded,O
that,O
of,O
the,O
en,O
‐,O
tire,O
SARS,O
crisis,O
.,O
In,O
comparison,O
with,O
SARS,O
‐,O
CoV,O
‐,O
1,NUMBER
.,O
the,O
infectivity,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
has,O
increased,O
but,O
the,O
virulence,O
has,O
weakened,O
.,O
The,O
reason,O
why,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
caused,O
the,O
severe,O
epidemic,O
is,O
directly,O
re,O
‐,O
lated,O
to,O
the,O
large,O
number,O
of,O
patients,O
with,O
mild,O
illness,CAUSE_OF_DEATH
.,O
Because,O
it,O
is,O
a,O
new,O
coronavirus,O
.,O
people,O
unconsciously,O
compared,O
it,O
with,O
SARS,O
‐,O
CoV,O
‐,O
1,NUMBER
and,O
MERS,O
‐,O
CoV,O
.,O
and,O
thus,O
felt,O
deceived,O
and,O
panicked,O
.,O
The,O
recovery,O
of,O
this,O
patient,O
with,O
severe,O
pneumonia,CAUSE_OF_DEATH
is,O
relatively,O
close,O
to,O
a,O
natural,O
outcome,O
and,O
the,O
antiviral,O
drugs,CRIMINAL_CHARGE
may,O
be,O
inef,O
‐,O
fective,O
.,O
The,O
characteristics,O
of,O
pulmonary,O
lesions,O
caused,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
are,O
different,O
from,O
ARDS,O
caused,O
by,O
traditional,O
ac,O
‐,O
quired,O
pneumonia,CAUSE_OF_DEATH
.,O
The,O
normal,O
lung,O
tissues,O
could,O
provide,O
fine,O
functional,O
compensation,O
.,O
resulting,O
in,O
mild,O
symptoms,O
and,O
serious,O
pulmonary,O
imaging,O
changes,O
.,O
which,O
should,O
be,O
taken,O
seriously,O
in,O
following,O
a,O
coping,O
strategy,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
can,O
be,O
transmitted,O
among,O
human,O
beings,O
.,O
Compared,O
with,O
SARS,O
‐,O
CoV,O
‐,O
1,NUMBER
.,O
its,O
infectivity,O
is,O
higher,O
but,O
its,O
virulence,O
is,O
weaker,O
;,O
hence,O
.,O
its,O
response,O
to,O
conventional,O
treatment,O
may,O
be,O
relatively,O
better,O
.,O
There,O
may,O
be,O
a,O
latent,O
trans,O
‐,O
mission,O
of,O
SARS,O
‐,O
CoV,O
‐,O
1,NUMBER
and,O
people,O
without,O
any,O
symptoms,O
can,O
also,O
transmit,O
the,O
virus,O
.,O
Timely,O
and,O
sufficient,O
noninvasive,O
respiratory,O
support,O
and,O
atomisation,O
are,O
effective,O
to,O
mitigate,O
the,O
respiratory,O
distress,O
.,O
Immunomodulatory,O
drugs,CRIMINAL_CHARGE
can,O
be,O
applied,O
appropriately,O
in,O
the,O
absence,O
of,O
excessive,O
Lixin,PERSON
Zhou1,PERSON
.,O
Weibiao,O
Wen1,O
.,O
Honglian,PERSON
Bai2,O
.,O
Fengyun,PERSON
Wang1,PERSON
.,O
Haiming,O
Yan2,O
.,O
Chang,PERSON
Li1,O
.,O
Minfeng,PERSON
Liang2,PERSON
.,O
Jiarong,O
Zhong1,O
.,O
Jinsong,PERSON
Shao1,PERSON
.,O
Tieou,O
Yu1,O
.,O
Xinhua,ORGANIZATION
Qiang1,O
.,O
Xiaofan,PERSON
Mao3,O
.,O
Kairong,PERSON
Lin3,PERSON
.,O
Zhanwen,O
Guan3,O
.,O
Yinong,O
Ye2,O
and,O
Wei,O
Luo3,O
Con,O
‐,O
flict,O
of,O
interest,O
:,O
L.,PERSON
Zhou,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
W.,PERSON
Wen,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
H.,PERSON
Bai,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
F.,PERSON
Wang,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
H.,PERSON
Yan,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
C.,PERSON
Li,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
M.,PERSON
Liang,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
J.,PERSON
Zhong,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
J.,PERSON
Shao,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
T.,PERSON
Yu,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
X.,PERSON
Qiang,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
X.,PERSON
Mao,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
Z.,PERSON
Guan,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
Y.,PERSON
Ye,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
W.,PERSON
Luo,PERSON
has,O
nothing,O
to,O
disclose,O
.,O
Zhu,PERSON
N,PERSON
.,O
Zhang,PERSON
D,PERSON
.,O
Wang,PERSON
W,PERSON
.,O
et,O
al,O
.,O
A,O
novel,O
coronavirus,O
from,O
patients,O
with,O
pneumonia,CAUSE_OF_DEATH
in,O
China,COUNTRY
.,O
2019,DATE
.,O
N,O
Engl,PERSON
J,PERSON
Med,PERSON
Xu,PERSON
Z,PERSON
.,O
Li,O
Y,O
.,O
Zhou,PERSON
J,PERSON
.,O
et,O
al,O
.,O
High,O
‐,O
flow,O
nasal,O
cannula,O
in,O
adults,O
with,O
acute,O
respiratory,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
and,O
after,O
extubation,O
:,O
a,O
ORIGINAL,O
RESEARCH,O
LETTER,O
|,O
L.,O
ZHOU,O
ET,O
AL,O
.,O
Rothe,PERSON
C,O
.,O
Schunk,PERSON
M,O
.,O
Sothmann,O
P,O
.,O
et,O
al,O
.,O
Transmission,O
of,O
2019,DATE
‐,O
nCoV,O
infection,CAUSE_OF_DEATH
from,O
an,O
asymptomatic,O
contact,O
in,O
Germany,COUNTRY
.,O
N,O
Engl,PERSON
J,PERSON
Med,PERSON
2020,DATE
;,O
382,NUMBER
:,O
970971,NUMBER
.,O
Chung,O
M,O
.,O
Bernheim,PERSON
A,O
.,O
Mei,PERSON
X,PERSON
.,O
et,O
al,O
.,O
CT,STATE_OR_PROVINCE
imaging,O
features,O
of,O
2019,DATE
novel,O
coronavirus,O
(,O
2019,DATE
‐,O
nCoV,O
),O
.,O
Radiology,O
2020,DATE
;,O
Wang,O
FY,O
.,O
Fang,O
B,O
.,O
Qiang,PERSON
XH,O
.,O
et,O
al,O
.,O
The,O
efficacy,O
and,O
immunomodula,O
‐,O
tory,O
effects,O
of,O
ulinastatin,O
and,O
thymosin,O
1,NUMBER
for,O
Force,O
ADT,ORGANIZATION
.,O
Ranieri,PERSON
VM,O
.,O
Rubenfeld,PERSON
GD,O
.,O
et,O
al,O
.,O
Acute,O
respiratory,O
distress,O
syndrome,O
:,O
the,O
Berlin,CITY
Definition,LOCATION
.,O
JAMA,PERSON
